Bedrijfsoverzicht
Bristol-Myers Squibb Company is a global biopharmaceutical entity dedicated to the discovery, development, licensing, manufacturing, marketing, distribution, and sale of specialized therapeutic products. The firm operates within the Healthcare sector, specifically classified under the Drug Manufacturers - General industry, which implies a focus on the research and commercialization of essential pharmaceutical solutions rather than consumer health products. With a market capitalization of $119.69B, an annual revenue of $48.19B, and an workforce of 32500 employees, the company represents a substantial entity within the pharmaceutical landscape. These valuation and revenue figures indicate that Bristol-Myers Squibb holds a significant market position, reflecting its capacity to generate substantial economic value and sustain a large-scale operational infrastructure across multiple therapeutic areas including oncology, hematology, immunology, cardiovascular, and neuroscience.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $48.19B, generating a net income of $7.05B and an EBITDA of $19.12B. The substantial gap between the revenue of $48.19B and the net income of $7.05B reveals a robust cost structure where operating expenses, including cost of goods sold and research and development costs, absorb approximately 85.4% of total revenue before arriving at the bottom line. Free cash flow stands at $11.15B, which signifies strong financial flexibility allowing the company to fund ongoing research initiatives, manage capital expenditures, or pursue strategic acquisitions without immediate reliance on external financing. Profitability is further dissected through three key margins: a Gross Margin of 72.6%, which indicates high pricing power and efficient production relative to sales; an Operating Margin of 28.2%, demonstrating effective control over operating expenses; and a Profit Margin of 14.6%, reflecting the final profitability after all costs and taxes. Regarding liquidity and leverage, the company holds $10.67B in cash against a total debt of $47.19B, resulting in a Debt to Equity ratio of 254.98, which characterizes a leveraged balance sheet typical for capital-intensive pharmaceutical firms. Short-term liquidity is supported by a Current Ratio of 1.25, indicating that the company possesses sufficient current assets to cover its current liabilities with a modest buffer. Management effectiveness is highlighted by a Return on Equity of 40.4% and a Return on Assets of 10.3%, metrics that demonstrate the firm's ability to generate significant returns on shareholder capital and utilize its asset base efficiently.
Waarderingsbeoordeling
Valuation metrics suggest the market prices Bristol-Myers Squibb based on both historical and future earnings expectations. The Trailing P/E Ratio is 16.94, while the Forward P/E is 9.52, implying that the market anticipates a significant acceleration in earnings growth in the coming year compared to the current run rate. The Price to Book ratio stands at 6.46, indicating that the stock trades at a substantial premium over its book value, reflecting the intangible value of intellectual property and future growth potential. Alternative valuation measures include a Price to Sales ratio of 2.48 and an EV/EBITDA of 8.16, which suggest the company is valued moderately relative to its sales volume and earnings before interest, taxes, depreciation, and amortization. In terms of trading range, the 52-week high is $62.89 and the 52-week low is $42.52, providing a clear context for current price positioning relative to the full year of volatility. The Beta value is 0.27, indicating that the stock's price volatility is significantly lower than the broader market, suggesting a defensive characteristic often found in established healthcare sectors.
Growth & Income
The company's growth profile is defined by a Revenue Growth of 1.3% and an Earnings Growth of 1392.1% year over year. The fact that earnings growth vastly outpaces revenue growth implies that recent earnings figures are likely driven by non-recurring items, accounting adjustments, or a base effect rather than sustained organic top-line expansion. As a consistent dividend payer, Bristol-Myers Squibb offers a Dividend Yield of 4.3% with a Payout Ratio of 72.0%. This payout ratio indicates that the company distributes a high proportion of its earnings to shareholders, which must be monitored to ensure sustainability given the specific earnings growth rate and overall profitability. The overall growth and income profile presents a scenario of stable cash generation supported by a high yield, though the divergent growth rates between revenue and earnings require careful interpretation regarding the underlying business performance.